Viking Therapeutics, Inc. - Common Stock (VKTX)

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

The company continues to make good progress with its key obesity treatment drug, VK2735.

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

The biotech player could eventually rival big pharma companies.

It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or mont

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose. Speaking at the Morgan Stanley Global Healthcare Conference, Pr

Both companies are approaching milestones that could light a fire under their stocks.

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

This company aims to serve a market heading toward $100 billion.

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic.

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current quarter.

They are fairly risky, but their potential upside is massive.